文献速递主动脉疾病

慢性肾脏病患者接受血管腔内主动脉修复术的选择标准

Selection criterion for endovascular aortic repair in those with chronic kidney disease.
PubMed 文献 · J Vasc Surg · 2023-01-31

基于血管质量倡议数据库的34,926例择期EVAR患者分析,比较实际1年死亡率与未修复预测1年死亡率。CKD 4期患者在各AAA大小下均无获益;CKD 5期患者AAA<5.5 cm时EVAR实际生存劣于未修复预测生存,仅AAA≥7.0 cm时EVAR才有实际死亡率获益。

要点

  • CKD 3b、4、5期患者为高危群体,按传统大小标准行择期EVAR可能不获益。
  • CKD 4期患者各AAA大小下EVAR实际1年死亡率与未修复预测1年死亡率无差异。
  • CKD 5期患者AAA<5.5 cm时EVAR实际1年生存劣于未修复预测生存,AAA≥7.0 cm时才有获益。

核心结论

  • 当前数据提示CKD 3b、4、5期患者为高危群体,按传统大小标准行择期EVAR可能不获益。
  • CKD 4、5期且AAA<5.5 cm患者不行择期EVAR获益。
  • CKD 5期患者择期EVAR可能需保留用于AAA≥7.0 cm者,除非存在其他令人担忧的解剖特征。

研究设计与样本

  • 利用血管质量倡议数据库识别因AAA行择期EVAR的患者,排除急诊或紧急修复者。
  • CKD分期基于术前估算肾小球滤过率(eGFR)和透析状态分类。
  • 通过修改可预测未修复1年死亡率的经验证合并症评分(Gagne指数)计算未治疗AAA的预测1年死亡率。
  • 主要结局为实际1年死亡率,与未修复预测1年死亡率比较。
  • 共34,926例患者符合研究标准。

主要发现

  • 不同CKD分类间Gagne指数存在差异。
  • CKD 4期和CKD 5期患者1年死亡率最高,其次为CKD 3b期,显著高于CKD 1期和CKD 2期。
  • CKD 4期患者在所有AAA大小下,EVAR实际1年死亡率与未行EVAR预测1年生存率无差异。
  • CKD 5期患者AAA<5.5 cm时,EVAR实际1年生存率劣于未行EVAR预测1年生存率。
  • CKD 5期患者仅AAA≥7.0 cm时,EVAR实际死亡率较未行EVAR预测1年死亡率有获益。

临床怎么用

  • 作者认为CKD 3b、4、5期患者按传统大小标准行择期EVAR可能不获益。
  • 作者认为CKD 4、5期且AAA<5.5 cm患者不行择期EVAR获益。
  • 作者认为CKD 5期患者择期EVAR可能需保留用于AAA≥7.0 cm者,除非存在其他令人担忧的解剖特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular aortic repair (EVAR) is the preferred method of repair for abdominal aortic aneurysms (AAAs). However, patients with advanced chronic kidney disease (CKD) are a high-risk group, and it is unknown which patients with CKD benefit from EVAR vs continued surveillance. The purpose of this study was to identify which patients with advanced CKD may benefit from EVAR. METHODS: The Vascular Quality Initiative Database was utilized to identify elective EVARs for AAAs. Patients were excluded if they underwent urgent or emergent repairs. CKD stages were categorized based on preoperative estimated glomular filtration rate (eGFR) and dialysis status. Predicted 1-year mortality of untreated AAAs was calculated by modifying a validated comorbidity score that predicts 1-year mortality (Gagne Index) without repair. The primary outcome was actual 1-year mortality, which was compared with the predicted 1-year mortality without repair. RESULTS: A total of 34,926 patient met study criteria. There were differences in Gagne Indices among the varying classes of CKD. Patients with CKD 4 and CKD 5 had the highest 1-year mortality rates, followed by CKD 3b, which was significantly higher than those with CKD 1 and CKD 2. Patients with CKD 4 had no differences between actual 1-year mortality with EVAR and predicted 1-year survival without EVAR across all AAA sizes. Those with CKD 5 had worse actual 1-year survival with EVAR than predicted 1-year survival without EVAR for AAAs <5.5 cm. Patients with CKD 5 only experienced an actual mortality benefit with EVAR compared with predicted 1-year mortality without EVAR for AAAs ≥7.0 cm. CONCLUSIONS: The current data suggest that patients with CKD 3b, 4, and 5 represent a high-risk group who may not benefit from elective EVAR utilizing traditional size criteria. Patients with CKD 4 and 5 with AAAs <5.5 cm do not benefit from elective EVAR. In patients with CKD 5, elective EVAR may need to be reserved for AAAs ≥7.0 cm unless there are other concerning anatomic characteristics.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Khoury MK, Thornton MA, Weaver FA, et al. Selection criterion for endovascular aortic repair in those with chronic kidney disease. J Vasc Surg. 2023. PMID: 36731756. doi:10.1016/j.jvs.2023.01.185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。